Global human papilloma virus vaccine implementation: An update
- 8 March 2018
- journal article
- review article
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 44 (6) , 989-997
Abstract
Human papillomavirus (HPV) infections continue to be one of the most common sexually transmitted infections worldwide. The oncogenic potential of this virus was well established in anogenital malignancies and oropharyngeal cancers. Even though a fall in cervical cancer rates has been reported worldwide, the subsequent rise in HPV‐associated head and neck cancers among men and women have been reported from developed countries, necessitating the vaccination of adolescent boys as well. The objective of this narrative review is to provide an update on the current status of HPV vaccination worldwide. This will be helpful for clinicians in counseling parents and guardians as this vaccine mainly targets sexually naïve preadolescents. An electronic search of the databases was carried out to retrieve information concerning HPV vaccine implementation between July 2006 and 2017, with special emphasis on the current viewpoints, controversies and ethical issues. Globally, 74 countries have implemented the HPV vaccine in the national immunization schedule, and this vaccine is listed as an essential medicine by WHO. About 60% of the low‐ and lower–middle‐income countries have implemented the vaccine with financial assistance from Gavi and WHO. The HPV vaccine is a safe vaccine with no serious adverse effects as per the data available from developed nations as well as low/lower middle/upper middle‐income countries. However, long‐term follow‐up is essential to substantiate the impact of the vaccination programs in cancer prevention.Keywords
Funding Information
- Indian Council of Medical Research (Project No: 5/8/7/15/2010/ECD-I)
This publication has 39 references indexed in Scilit:
- Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conferencePreventive Medicine, 2017
- Safety and Immunogenicity of a 9-Valent Human Papillomavirus Vaccine Administered to 9- to 15-Year-Old Japanese GirlsJapanese Journal of Infectious Diseases, 2017
- Parents who refuse or delay HPV vaccine: Differences in vaccination behavior, beliefs, and clinical communication preferencesHuman Vaccines & Immunotherapeutics, 2016
- Human papillomavirus vaccination: Review and roll out plan in DelhiCHRISMED Journal of Health and Research, 2016
- US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV VaccinesJNCI: Journal of the National Cancer Institute, 2015
- Cervical cancer: Can it be prevented?World Journal of Clinical Oncology, 2014
- Potential cost‐effectiveness of the nonavalent human papillomavirus (HPV) vaccineInternational Journal of Cancer, 2013
- Human Papillomavirus and VaccinationMayo Clinic Proceedings, 2008
- Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis updateInternational Journal of Cancer, 2007
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003